MedTrace Logo

In-depth Characterization of Circulating and Infiltrating Immune Subsets and Tumor Cells in Cancer Patients

NCT06827639 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 640

Last updated 2025-02-14

No results posted yet for this study

Summary

The aim of this study is to describe the tumor microenvironment of solid tumors and to understand the changes induced by anti-cancer treatments, particularly those developed by Innate Pharma. Innate Pharma is a biotechnology company which discovers and develops therapeutic antibodies that exploit the innate immune system to improve cancer treatment. Thanks to this study, it will be possible to correlate clinical and immunological characteristics with the patient\'s clinical features. The analyses generated will contribute to the design and improvement of innovative therapeutic antibodies acting on the immune system

Conditions

Interventions

PROCEDURE

blood collection

Blood sampling is performed during Scrrening / visit 1 for patients enrolled in cohort 1, cohort 2 and cohort 3

PROCEDURE

tissue specimen collection

In Cohort 1- patients with solid tumor undergoing surgery, fresh tissue specimen is collected during surgery

Sponsors & Collaborators

  • Assistance Publique Hopitaux De Marseille

    lead OTHER

Principal Investigators

  • Frederic VELY, Dr · Assistance Publique Hôpitaux de Marseille

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-04-30
Primary Completion
2028-04-30
Completion
2028-04-30

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06827639 on ClinicalTrials.gov